US plans shift of Merck COVID treatment to commercial market

ایران اخبار اخبار

US plans shift of Merck COVID treatment to commercial market
ایران آخرین اخبار,ایران سرفصلها

By Michael Erman (Reuters) - The U.S. government will stop distributing free doses of Merck & Co's COVID-19 antiviral treatment molnupiravir by the ...

  • 📰 SaltWire Network
  • ⏱ Reading Time:
  • 33 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 16%
  • Publisher: 63%

- The U.S. government will stop distributing free doses of Merck & Co's COVID-19 antiviral treatment molnupiravir by the middle of next month and expects it to be sold on the commercial market instead.

Merck, which developed the drug with Ridgeback Biotherapeutics, said in an emailed statement on Wednesday that it needs an updated letter of authorization from the U.S. Food and Drug Administration to allow it to start selling the drug commercially. It has taken a backseat to Paxlovid in the United States and the EU regulator recommended against the Merck drug's use in the region.

It has also been linked to potentially transmissable mutations in the COVID-19 virus, according to a study published in the journal Nature last month. Merck said the study was limited and that it is confident in the clinical profile of the drug.

این خبر را خلاصه کرده ایم تا بتوانید سریع آن را بخوانید. اگر به خبر علاقه مند هستید، می توانید متن کامل را اینجا بخوانید. ادامه مطلب:

SaltWire Network /  🏆 45. in İR
 

ایران آخرین اخبار, ایران سرفصلها



Render Time: 2025-01-13 20:52:50